Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. The partial legal win against Avadel helps protect Jazz's market position in idiopathic hypersomnia through 2036 and Jazz should also receive royalties on net sales of Lumryz. The unexpected phase 3 trial win of Zepzelca in combination with Tecentriq could add more than $400-500 million in annual net sales by the end of the decade.
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Jazz Pharmaceuticals plc JAZZ revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG's RHHBY atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab.
Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market
Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new biliary tract cancer drug; Zanidatamab.
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Jazz (JAZZ) Up 1.1% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
Wall Street Analysts Believe Jazz (JAZZ) Could Rally 56.66%: Here's is How to Trade
The consensus price target hints at a 56.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Jazz Pharmaceuticals (JAZZ) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investing in Jazz (JAZZ)? Don't Miss Assessing Its International Revenue Trends
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.
Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript
Jazz Pharmaceuticals plc. (NASDAQ:JAZZ ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renée Galá - President and Chief Operating Officer Rob Iannone - Executive Vice President and Global Head-R&D Phil Johnson - Executive Vice President and Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Marc Goodman - Leerink Jessica Fye - JPMorgan Annabel Samimy - Stifel.
